These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 31362850)

  • 1. Defining and Modulating 'BRCAness'.
    Byrum AK; Vindigni A; Mosammaparast N
    Trends Cell Biol; 2019 Sep; 29(9):740-751. PubMed ID: 31362850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA repair and cell cycle checkpoint defects in a mouse model of 'BRCAness' are partially rescued by 53BP1 deletion.
    Misenko SM; Patel DS; Her J; Bunting SF
    Cell Cycle; 2018; 17(7):881-891. PubMed ID: 29620483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality.
    Murai J; Pommier Y
    Cancer Res; 2023 Apr; 83(8):1173-1174. PubMed ID: 37057596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
    Stok C; Kok YP; van den Tempel N; van Vugt MATM
    Nucleic Acids Res; 2021 May; 49(8):4239-4257. PubMed ID: 33744950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.
    Abbotts R; Topper MJ; Biondi C; Fontaine D; Goswami R; Stojanovic L; Choi EY; McLaughlin L; Kogan AA; Xia L; Lapidus R; Mahmood J; Baylin SB; Rassool FV
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22609-22618. PubMed ID: 31591209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARPi focus the spotlight on replication fork protection in cancer.
    Schlacher K
    Nat Cell Biol; 2017 Oct; 19(11):1309-1310. PubMed ID: 29087384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploiting replication gaps for cancer therapy.
    Cong K; Cantor SB
    Mol Cell; 2022 Jul; 82(13):2363-2369. PubMed ID: 35568026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
    Murai J
    Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
    Haynes B; Murai J; Lee JM
    Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic exploitation of tumor cell defects in homologous recombination.
    Powell SN; Kachnic LA
    Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer.
    Hu Y; Guo M
    Cancer Sci; 2020 Sep; 111(9):3111-3121. PubMed ID: 32639661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Mechanism to Induce BRCAness in Cancer Cells.
    Cai C
    Cancer Res; 2020 Jul; 80(14):2977-2978. PubMed ID: 32669350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCAness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality.
    Li X; Zou L
    J Clin Invest; 2024 Jul; 134(14):. PubMed ID: 39007266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.
    Lim D; Ngeow J
    Endocr Relat Cancer; 2016 Jun; 23(6):R267-85. PubMed ID: 27226207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCAness revisited.
    Lord CJ; Ashworth A
    Nat Rev Cancer; 2016 Feb; 16(2):110-20. PubMed ID: 26775620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.
    Chalasani P; Livingston R
    Oncologist; 2013; 18(8):909-16. PubMed ID: 23881989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.